A proven tool for local tumor control
TheraSphere is the first and only FDA approved transarterial radiation therapy for hepatocellular carcinoma (HCC), delivering maximum damage to the tumor, sparing healthy tissue, and preserving treatment options.
How TheraSphere works
TheraSphere is a treatment consisting of millions of tiny glass beads – each thinner than a strand of hair – containing radioactive Yttrium-90.
Administered by an Interventional Radiologist, each glass bead delivers a highly concentrated dose of radiation that targets the HCC liver tumor via the hepatic artery.
Stay up to date
Receive emails on relevant clinical data and news.
Offer more possibilities
In combination with other therapies, TheraSphere can offer patients more treatment possibilities and maintain quality of life.
See how TheraSphere gave Nicole treatment options that ultimately saved her life.
|Studied across all BCLC stages1||Minimally invasive outpatient procedure2||Maintains patient eligibility for future treatment|
TheraSphere treatment centers
Instantly locate treatment centers administering TheraSphere near you for your patients.
Have a field representative get in touch with you to learn more about the clinical benefits and possibilities that TheraSphere can offer your patients.
* LEGACY. Hepatology. 2021
- Salem R et al. Hepatology 2018; 68(4): 1429-40
- Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
- Gabr, A., Kulik, L., Mouli, S., Riaz, A., Ali, R., Desai, K., Mora, R.A., Ganger, D., Maddur, H., Flamm, S., Boike, J., Moore, C., Thornburg, B., Alasadi, A., Baker, T., Borja‐Cacho, D., Katariya, N., Ladner, D.P., Caicedo, J.C., Lewandowski, R.J. and Salem, R. (2020), Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐year Experience in 207‐Patient Cohort. Hepatology. Accepted Author Manuscript. doi:10.1002/hep.31318 >=30% hepatic reserve.
- Lewandowski RJ, Gabr A, Abouchaleh N et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018; 287(3): 1050-1058.